| ￥5800 | |
| Z04464-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 54.8 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 60-66 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22μm filtered solution in 20mM PB, 250mM NaCl (pH 7.4). | ||||
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | Fibrinogen-like protein 1 (FGL-1) is a protein that is structurally related to fibrinogen. In humans, FLG-1 is encoded by the FGL1 gene.Fibrinogen-like protein 1 is a member of the fibrinogen family of proteins, which also includes fibrinogen, fibrinogen-like protein 2, and clotting factors V, VIII, and XIII.Fibrinogen-like Protein 1 is a major immune inhibitory ligand of LAG-3. |
| Synonyms | FGL1; FGL-1; Hepassocin; HP-041; HFREP-1; LFIRE-1; HFREP1; Lag3 ligand |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
